Literature DB >> 33631752

Comparison of Approaches for Prediction of Renal Replacement Therapy-Free Survival in Patients with Acute Kidney Injury.

Pattharawin Pattharanitima1,2, Akhil Vaid1, Suraj K Jaladanki3, Ishan Paranjpe3, Ross O'Hagan3, Kinsuk Chauhan1, Tielman T Van Vleck4, Aine Duffy4, Kumardeep Chaudhary4, Benjamin S Glicksberg5, Javier A Neyra6, Steven G Coca1, Lili Chan7, Girish N Nadkarni1,4.   

Abstract

BACKGROUND/AIMS: Acute kidney injury (AKI) in critically ill patients is common, and continuous renal replacement therapy (CRRT) is a preferred mode of renal replacement therapy (RRT) in hemodynamically unstable patients. Prediction of clinical outcomes in patients on CRRT is challenging. We utilized several approaches to predict RRT-free survival (RRTFS) in critically ill patients with AKI requiring CRRT.
METHODS: We used the Medical Information Mart for Intensive Care (MIMIC-III) database to identify patients ≥18 years old with AKI on CRRT, after excluding patients who had ESRD on chronic dialysis, and kidney transplantation. We defined RRTFS as patients who were discharged alive and did not require RRT ≥7 days prior to hospital discharge. We utilized all available biomedical data up to CRRT initiation. We evaluated 7 approaches, including logistic regression (LR), random forest (RF), support vector machine (SVM), adaptive boosting (AdaBoost), extreme gradient boosting (XGBoost), multilayer perceptron (MLP), and MLP with long short-term memory (MLP + LSTM). We evaluated model performance by using area under the receiver operating characteristic (AUROC) curves.
RESULTS: Out of 684 patients with AKI on CRRT, 205 (30%) patients had RRTFS. The median age of patients was 63 years and their median Simplified Acute Physiology Score (SAPS) II was 67 (interquartile range 52-84). The MLP + LSTM showed the highest AUROC (95% CI) of 0.70 (0.67-0.73), followed by MLP 0.59 (0.54-0.64), LR 0.57 (0.52-0.62), SVM 0.51 (0.46-0.56), AdaBoost 0.51 (0.46-0.55), RF 0.44 (0.39-0.48), and XGBoost 0.43 (CI 0.38-0.47).
CONCLUSIONS: A MLP + LSTM model outperformed other approaches for predicting RRTFS. Performance could be further improved by incorporating other data types.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Acute kidney injury; Continuous renal replacement therapy; Discontinuation; Machine learning; Mortality

Mesh:

Year:  2021        PMID: 33631752     DOI: 10.1159/000513700

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  5 in total

Review 1.  Machine Learning for Acute Kidney Injury Prediction in the Intensive Care Unit.

Authors:  Eric R Gottlieb; Mathew Samuel; Joseph V Bonventre; Leo A Celi; Heather Mattie
Journal:  Adv Chronic Kidney Dis       Date:  2022-09       Impact factor: 4.305

Review 2.  Can Artificial Intelligence Assist in Delivering Continuous Renal Replacement Therapy?

Authors:  Nada Hammouda; Javier A Neyra
Journal:  Adv Chronic Kidney Dis       Date:  2022-09       Impact factor: 4.305

3.  Explainable Machine Learning-Based Risk Prediction Model for In-Hospital Mortality after Continuous Renal Replacement Therapy Initiation.

Authors:  Pei-Shan Hung; Pei-Ru Lin; Hsin-Hui Hsu; Yi-Chen Huang; Shin-Hwar Wu; Chew-Teng Kor
Journal:  Diagnostics (Basel)       Date:  2022-06-19

4.  Nursing Countermeasures of Continuous Renal Replacement Treatment in End-Stage Renal Disease with Refractory Hypotension in the Context of Smart Health.

Authors:  Liya Ma; Jianli Guo; Hongwei Sun; Nan Li; MeiXuan Lv; Bing Shang
Journal:  Comput Math Methods Med       Date:  2022-08-10       Impact factor: 2.809

5.  Accuracy of clinicians' ability to predict the need for renal replacement therapy: a prospective multicenter study.

Authors:  Alexandre Sitbon; Michael Darmon; Guillaume Geri; Paul Jaubert; Pauline Lamouche-Wilquin; Clément Monet; Lucie Le Fèvre; Marie Baron; Marie-Line Harlay; Côme Bureau; Olivier Joannes-Boyau; Claire Dupuis; Damien Contou; Virginie Lemiale; Marie Simon; Christophe Vinsonneau; Clarisse Blayau; Frederic Jacobs; Lara Zafrani
Journal:  Ann Intensive Care       Date:  2022-10-15       Impact factor: 10.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.